These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21621965)

  • 1. Epothilone-induced peripheral neuropathy: a review of current knowledge.
    Argyriou AA; Marmiroli P; Cavaletti G; Kalofonos HP
    J Pain Symptom Manage; 2011 Dec; 42(6):931-40. PubMed ID: 21621965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neuropathy induced by microtubule-stabilizing agents.
    Lee JJ; Swain SM
    J Clin Oncol; 2006 Apr; 24(10):1633-42. PubMed ID: 16575015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
    Villanueva C; Dufresne A; Pivot X; Viel E
    Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
    Vahdat LT; Thomas ES; Roché HH; Hortobagyi GN; Sparano JA; Yelle L; Fornier MN; Martín M; Bunnell CA; Mukhopadhyay P; Peck RA; Perez EA
    Support Care Cancer; 2012 Nov; 20(11):2661-8. PubMed ID: 22382588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epothilones in the treatment of ovarian cancer.
    Diaz-Padilla I; Oza AM
    Future Oncol; 2011 Apr; 7(4):559-68. PubMed ID: 21463144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epothilones: clinical update and future directions.
    Donovan D; Vahdat LT
    Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents.
    Argyriou AA; Zolota V; Kyriakopoulou O; Kalofonos HP
    J BUON; 2010; 15(3):435-46. PubMed ID: 20941808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
    Cigler T; Vahdat L
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review on oxaliplatin-induced peripheral nerve damage.
    Argyriou AA; Polychronopoulos P; Iconomou G; Chroni E; Kalofonos HP
    Cancer Treat Rev; 2008 Jun; 34(4):368-77. PubMed ID: 18281158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatological toxicity of ixabepilone.
    Conlin AK; Vahdat L
    Anticancer Res; 2006; 26(3B):2279-80. PubMed ID: 16821602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
    Morris PG; Fornier MN
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.
    Bosch-Barrera J; Espinós J; Gómez-Ibáñez A; Gállego Pérez-Larraya J; Iriarte J
    Clin Transl Oncol; 2009 Nov; 11(11):765-7. PubMed ID: 19917541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach.
    Carlson K; Ocean AJ
    Clin Breast Cancer; 2011 Apr; 11(2):73-81. PubMed ID: 21569993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
    Pivot X; Villanueva C; Chaigneau L; Nguyen T; Demarchi M; Maurina T; Stein U; Borg C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):593-9. PubMed ID: 18363523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.